©The Author(s) 2026.
World J Diabetes. Feb 15, 2026; 17(2): 112867
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112867
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112867
Figure 2 Comparison of clinical efficacy between two groups of patients.
CM: Canagliflozin monotherapy; CSCT: Canagliflozin and semaglutide combination therapy.
- Citation: Miao Y, He P, Wang DY, Yan L, Cao HX, Shao FM. Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy. World J Diabetes 2026; 17(2): 112867
- URL: https://www.wjgnet.com/1948-9358/full/v17/i2/112867.htm
- DOI: https://dx.doi.org/10.4239/wjd.v17.i2.112867